-+ 0.00%
-+ 0.00%
-+ 0.00%
Immutep's Efti Combination Maintains Quality of Life in Phase II Sarcoma Trial
Share
Listen to the news
Immutep's Efti Combination Maintains Quality of Life in Phase II Sarcoma Trial
  • Immutep announced Phase II EFTISARC-NEO results showing stable quality of life during preoperative treatment for resectable soft tissue sarcoma.
  • The trial evaluated eftilagimod alfa with pembrolizumab and radiotherapy in 40 patients.
  • Following surgery, patients reported significantly improved quality of life, including reduced fatigue and better daily functioning.
  • Results are being presented at ESMO 2026, running October 23-27 in Madrid.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on October 23, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending